JP2007500237A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500237A5
JP2007500237A5 JP2006533499A JP2006533499A JP2007500237A5 JP 2007500237 A5 JP2007500237 A5 JP 2007500237A5 JP 2006533499 A JP2006533499 A JP 2006533499A JP 2006533499 A JP2006533499 A JP 2006533499A JP 2007500237 A5 JP2007500237 A5 JP 2007500237A5
Authority
JP
Japan
Prior art keywords
substituted
compound
aryl
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/016954 external-priority patent/WO2004111058A1/en
Publication of JP2007500237A publication Critical patent/JP2007500237A/ja
Publication of JP2007500237A5 publication Critical patent/JP2007500237A5/ja
Pending legal-status Critical Current

Links

JP2006533499A 2003-05-30 2004-05-27 抗癌剤としてのヘテロアリール縮合ピリミジニル化合物 Pending JP2007500237A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47468403P 2003-05-30 2003-05-30
PCT/US2004/016954 WO2004111058A1 (en) 2003-05-30 2004-05-27 Heteroryl-fused pyrimidinyl compounds as anticancer agents

Publications (2)

Publication Number Publication Date
JP2007500237A JP2007500237A (ja) 2007-01-11
JP2007500237A5 true JP2007500237A5 (enExample) 2007-08-23

Family

ID=33551504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533499A Pending JP2007500237A (ja) 2003-05-30 2004-05-27 抗癌剤としてのヘテロアリール縮合ピリミジニル化合物

Country Status (10)

Country Link
US (2) US7345046B2 (enExample)
EP (1) EP1636238A1 (enExample)
JP (1) JP2007500237A (enExample)
KR (1) KR20060054187A (enExample)
CN (1) CN100418971C (enExample)
AU (1) AU2004247650A1 (enExample)
CA (1) CA2526217A1 (enExample)
MX (1) MXPA05012706A (enExample)
TW (1) TW200505454A (enExample)
WO (1) WO2004111058A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
DE602004021477D1 (de) * 2003-03-07 2009-07-23 Astrazeneca Ab Kondensierte heterocyclen und deren verwendungen
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1732926B1 (en) * 2004-04-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Mitotic kinesin inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
UA84954C2 (ru) * 2004-07-22 2008-12-10 Astrazeneca Ab Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
RU2007109867A (ru) * 2004-08-18 2008-09-27 Астразенека Аб (Se) Выбранные конденсированные гетероциклы и их применение
MY141233A (en) * 2004-08-18 2010-03-31 Astrazeneca Ab Enantiomers of selected fused heterocyclics and uses thereof
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
WO2006098962A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Compounds for inhibiting ksp kinesin activity
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
JP2008533018A (ja) * 2005-03-09 2008-08-21 シェーリング コーポレイション KSPキネシン活性を阻害するための縮合チエノ[2,3−b]ピリジン化合物および縮合チアゾロ[5,4−b]ピリジン化合物
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
MX2007014117A (es) 2005-05-13 2008-02-05 Virochem Pharma Inc Compuestos y metodos para el tratamiento o prevencion de infecciones de flavivirus.
AU2011205048B2 (en) * 2005-05-13 2013-05-02 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
US20090214529A9 (en) * 2007-05-22 2009-08-27 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3240541A4 (en) * 2014-12-29 2018-07-25 New Mexico Tech Research Foundation Synthetic rigidin analogues as anti-cancer agents, salts, solvates and prodrugs thereof, and method of producing same
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのrasスーパーファミリーと相互作用する化合物
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720969B2 (ja) * 1988-03-02 1995-03-08 吉富製薬株式会社 3,4―ジヒドロチエノ〔2,3―d〕ピリミジン化合物およびその医薬用途
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
KR100883184B1 (ko) 2000-12-11 2009-02-12 암젠 인코포레이션 Cxcr3 길항제
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
EP1465896A4 (en) 2001-12-06 2006-01-11 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2485343A1 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods

Similar Documents

Publication Publication Date Title
JP4778439B2 (ja) 抗癌剤としてのキナゾリノン化合物
JP2007500237A5 (enExample)
US7345046B2 (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP1636225B1 (en) Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
JP2007518822A (ja) 抗癌剤としてのテトラヒドロカルボリン化合物
JP2007512368A5 (enExample)
AU2006236557A1 (en) 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases
JP2025522388A (ja) Kras阻害剤としてのテトラヒドロピリド3,4-dピリミジン誘導体
KR20060135035A (ko) 유사분열 키네신 억제제
MXPA06005844A (en) Quinazolinone compounds as anticancer agents